Central nervous system (CNS) tumors account for about 2% of all cancers with the annually incidence 9.5 cases out of 100,000 people. Recently there has been a significant expansion of knowledge in the neuro-oncology domain regarding the onset and development of neoplastic disease at the genetic as well as epigenetic levels. Novel prognostic and predictive biomarkers are emerging and the fundamental view of the histological-based classification of CNS tumors is gradually changing. The huge progress in genetic and epigenetic findings led to the very recent update of World Health Organization CNS tumors classification in 2016. For the first time, the molecular biomarkers are incorporated in addition to histopathology to refine the diagnoses of many tumor entities. The main objective of the project will be the research of molecular-genetic biomarkers of the primary CNS tumors in well-designed clinical studies that will help with more precise diagnosis and better prediction of patient´s prognosis and treatment response.
- assigned by the advisor